Core Lab's Q3 Net Income Jumps Amidst Debt Reduction

Ticker: CLB · Form: 10-Q · Filed: Oct 23, 2025 · CIK: 1958086

Sentiment: mixed

Topics: Oil & Gas Services, Earnings Report, Debt Reduction, Share Repurchase, Financial Performance, Energy Sector, 10-Q Filing

Related Tickers: CLB, SLB, HAL

TL;DR

**CLB is quietly deleveraging and buying back stock, making it a solid long-term play despite flat revenue.**

AI Summary

Core Laboratories Inc. reported a mixed financial performance for the three and nine months ended September 30, 2025. For the three months, total revenue slightly increased to $134.521 million from $134.397 million in the prior year, driven by a rise in services revenue to $101.125 million from $98.842 million. Net income attributable to Core Laboratories Inc. also saw a positive jump, reaching $14.239 million, up from $11.745 million in Q3 2024. However, for the nine months, total revenue decreased to $388.265 million from $394.611 million, primarily due to a decline in product sales to $95.830 million from $102.937 million. Despite this, net income attributable to Core Laboratories Inc. for the nine months increased to $24.721 million from $23.997 million. The company significantly increased its common stock repurchases, spending $9.770 million in the nine months ended September 30, 2025, compared to $402 thousand in the same period of 2024. Long-term debt decreased to $114.103 million at September 30, 2025, from $126.111 million at December 31, 2024, reflecting strategic debt reduction efforts.

Why It Matters

Core Laboratories' ability to increase net income despite a slight revenue dip for the nine-month period, coupled with significant debt reduction and share repurchases, signals a focus on shareholder value and financial health. This could attract investors seeking stable, well-managed companies in the volatile oil and gas services sector. For employees, a financially stronger company potentially offers greater job security and opportunities. Customers might benefit from continued investment in services, enhancing the company's competitive edge against rivals like Schlumberger or Halliburton, who also vie for market share in reservoir optimization and production enhancement.

Risk Assessment

Risk Level: medium — The company's revenue for the nine months ended September 30, 2025, decreased by $6.346 million to $388.265 million, primarily due to a $7.107 million decline in product sales. This indicates potential market headwinds or competitive pressures. Additionally, the geopolitical conflict between Russia and Ukraine, while not currently impacting operations significantly, remains an ongoing risk factor that could disrupt future business.

Analyst Insight

Investors should consider Core Laboratories Inc. (CLB) for its strategic debt reduction of $12.008 million and increased share repurchases of $9.770 million, which demonstrate a commitment to improving shareholder returns. Monitor future revenue trends, especially in product sales, to ensure the company can sustain its profitability and financial strength amidst market fluctuations.

Financial Highlights

debt To Equity
N/A
revenue
$134.521M
operating Margin
N/A
total Assets
N/A
total Debt
$114.103M
net Income
$14.239M
eps
$0.31
gross Margin
N/A
cash Position
$25.629M
revenue Growth
+0.09%

Revenue Breakdown

SegmentRevenueGrowth
Services Revenue$101.125M+2.31%
Product Sales$95.830M-6.91%

Key Numbers

Key Players & Entities

FAQ

What were Core Laboratories Inc.'s total revenues for the three months ended September 30, 2025?

Core Laboratories Inc. reported total revenues of $134.521 million for the three months ended September 30, 2025, a slight increase from $134.397 million in the same period of 2024.

How did Core Laboratories Inc.'s net income attributable to the company change in Q3 2025?

Net income attributable to Core Laboratories Inc. for the three months ended September 30, 2025, was $14.239 million, an increase from $11.745 million in the third quarter of 2024.

What was the trend in Core Laboratories Inc.'s long-term debt?

Core Laboratories Inc.'s long-term debt decreased to $114.103 million at September 30, 2025, from $126.111 million at December 31, 2024, indicating a reduction of $12.008 million.

Did Core Laboratories Inc. repurchase common stock in 2025?

Yes, Core Laboratories Inc. repurchased $9.770 million of common stock during the nine months ended September 30, 2025, a significant increase compared to $402 thousand in the same period of 2024.

What were Core Laboratories Inc.'s basic earnings per share for the nine months ended September 30, 2025?

Basic earnings per share attributable to Core Laboratories Inc. for the nine months ended September 30, 2025, was $0.53, up from $0.51 in the corresponding period of 2024.

How much cash did Core Laboratories Inc. have at the end of Q3 2025?

As of September 30, 2025, Core Laboratories Inc. reported cash and cash equivalents of $25.629 million, an increase from $19.157 million at December 31, 2024.

What is Core Laboratories Inc.'s outlook on the geopolitical conflict in Russia and Ukraine?

As of September 30, 2025, Core Laboratories Inc.'s laboratory facilities, offices, and locations in Russia and Ukraine continued to operate with no significant impact to local business operations, and no impairment assessments were performed.

What new accounting pronouncements will affect Core Laboratories Inc.'s disclosures?

Core Laboratories Inc. will expand disclosures regarding income taxes due to ASU 2023-09 (effective after December 15, 2024), expenses due to ASU 2024-03 (effective after December 15, 2026), and credit losses due to ASU 2025-05 (effective after December 15, 2025).

What were Core Laboratories Inc.'s total assets at September 30, 2025?

Core Laboratories Inc. reported total assets of $591.360 million at September 30, 2025, a slight increase from $590.406 million at December 31, 2024.

How much did Core Laboratories Inc. spend on capital expenditures for operations in the first nine months of 2025?

Core Laboratories Inc. spent $8.265 million on capital expenditures for operations during the nine months ended September 30, 2025, compared to $8.647 million in the same period of 2024.

Risk Factors

Industry Context

Core Laboratories operates within the oilfield services sector, which is intrinsically linked to global energy demand and commodity prices. The industry is characterized by cyclicality, technological innovation, and increasing pressure for sustainable practices. Competitors range from large diversified service providers to specialized niche players.

Regulatory Implications

The oil and gas industry faces evolving environmental regulations globally. Companies like Core Laboratories must navigate compliance with emissions standards, waste management, and potential carbon pricing mechanisms, which could impact operational costs and service offerings.

What Investors Should Do

  1. Monitor oil and gas price trends.
  2. Analyze the sustainability of services revenue growth.
  3. Evaluate the impact of increased stock repurchases.
  4. Assess the company's debt reduction strategy.

Key Dates

Glossary

Basic EPS Attributable to CLB
Earnings Per Share calculated by dividing net income attributable to common shareholders by the weighted-average number of outstanding common shares. (Indicates profitability on a per-share basis, showing an increase to $0.31 for Q3 2025 and $0.53 year-to-date.)
Net Cash Provided by Operating Activities
The net amount of cash generated from a company's normal business operations over a period. (A key indicator of financial health, showing a decrease to $29.085M for the nine months ended September 30, 2025, compared to the prior year.)
Common Stock Repurchases
The company buying back its own shares from the open market. (Indicates a significant increase in capital return to shareholders, with $9.770M spent in YTD Q3 2025, up from $402K in the prior year.)

Year-Over-Year Comparison

Compared to the prior year, Core Laboratories reported a slight increase in Q3 2025 total revenue ($134.521M vs $134.397M) driven by services, and a notable rise in net income ($14.239M vs $11.745M). However, year-to-date revenue saw a decrease ($388.265M vs $394.611M) due to lower product sales. Operating cash flow also declined ($29.085M vs $35.773M), while stock repurchases surged significantly ($9.770M vs $402K).

Filing Stats: 4,347 words · 17 min read · ~14 pages · Grade level 15.2 · Accepted 2025-10-23 16:05:04

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Page Item 1.

Financial Statements

Financial Statements Consolidated Balance Sheets at September 30, 2025 (Unaudited) and December 31, 2024 3 Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 4 Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 ( Unaudited) 6 Consolidated Statements of Changes in Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 7 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 9 Notes to the Interim Consolidated Financial Statements (Unaudited) 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 35

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 36 Item 5. Other Information 37 Item 6. Exhibits 38 Signature 39

- FINANCI AL INFORMATION

PART I - FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements CORE LABORATORIES INC. CONSOLIDATED B ALANCE SHEETS (In thousands, except share and per share data) September 30, 2025 December 31, 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 25,629 $ 19,157 Accounts receivable, net of allowance for credit losses of $ 5,296 and $ 3,192 at 2025 and 2024, respectively 110,258 111,761 Inventories 58,241 59,402 Prepaid expenses 10,056 10,176 Income taxes receivable 14,716 15,594 Other current assets 8,014 10,516 TOTAL CURRENT ASSETS 226,914 226,606 PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $ 321,113 and $ 314,317 at 2025 and 2024, respectively 98,031 97,063 RIGHT OF USE ASSETS 53,980 56,488 INTANGIBLES, net of accumulated amortization and impairment of $ 19,470 and $ 19,326 at 2025 and 2024, respectively 6,107 6,403 GOODWILL 100,012 99,445 DEFERRED TAX ASSETS, net 70,506 69,613 OTHER ASSETS 35,810 34,788 TOTAL ASSETS $ 591,360 $ 590,406 LIABILITIES AND EQUITY CURRENT LIABILITIES: Accounts payable $ 36,945 $ 34,549 Accrued payroll and related costs 23,363 22,901 Taxes other than payroll and income 3,852 7,106 Unearned revenues 7,258 9,332 Operating lease liabilities 11,474 10,690 Income taxes payable 3,513 4,851 Other current liabilities 9,338 8,157 TOTAL CURRENT LIABILITIES 95,743 97,586 LONG-TERM DEBT, net 114,103 126,111 LONG-TERM OPERATING LEASE LIABILITIES 41,525 43,343 DEFERRED COMPENSATION 31,054 31,115 DEFERRED TAX LIABILITIES, net 10,102 13,783 OTHER LONG-TERM LIABILITIES 21,445 20,732 COMMITMENTS AND CONTINGENCIES EQUITY: Preference stock, 6,000,000 shares authorized, $ 0.01 par value; none issued or outstanding — — Common stock, 200,000,000 shares authorized, $ 0.01 par value, 46,966,868 issued and 46,086,944 outstanding at 2025; 46,966,868 is

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing